 |
14 Diseases |  |
3 Trials |
|
3 Trials |  |
126 News |  |
| «12 |
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Jan 10, 2019
P4, N=100, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Feb 2019 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Apr 2019
- || adavosertib (AZD1775) / AstraZeneca
Trial completion date, Trial primary completion date: AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies (clinicaltrials.gov) - Dec 12, 2018
P1, N=52, Recruiting, Sponsor: AstraZeneca
Trial completion date: Feb 2019 --> Oct 2019 | Trial primary completion date: Nov 2018 --> Apr 2019 Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020
- || adavosertib (AZD1775) / AstraZeneca
Trial completion, Metastases: Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Apr 30, 2018
P1, N=31, Completed, Sponsor: AstraZeneca
Trial completion date: Aug 2019 --> Aug 2020 | Trial primary completion date: Aug 2019 --> Aug 2020 Active, not recruiting --> Completed
- | ondansetron intravenous / Generic mfg., granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Biomarker, New P4 trial: Pharmacogenomics and Post-Operative Nausea and Vomiting (clinicaltrials.gov) - Apr 18, 2018
P4, N=100, Not yet recruiting, Sponsor: Mayo Clinic
- | Sancuso (granisetron) / Solasia
New P2 trial: Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section (clinicaltrials.gov) - Mar 30, 2018
P2, N=40, Not yet recruiting, Sponsor: Assiut University
- adavosertib (AZD1775) / AstraZeneca
Enrollment closed, Metastases: Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Mar 23, 2018
P1, N=31, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- adavosertib (AZD1775) / AstraZeneca
Enrollment open: AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies (clinicaltrials.gov) - Nov 27, 2017
P1, N=48, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Nov 17, 2017
P2, N=212, Completed, Sponsor: Assiut University
Not yet recruiting --> Recruiting Recruiting --> Completed | N=120 --> 212 | Trial primary completion date: Aug 2017 --> May 2017
- | adavosertib (AZD1775) / AstraZeneca
New P1 trial, Metastases: Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours (clinicaltrials.gov) - Oct 19, 2017
P1, N=24, Recruiting, Sponsor: AstraZeneca
- | adavosertib (AZD1775) / AstraZeneca
New P1 trial: AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies (clinicaltrials.gov) - Oct 18, 2017
P1, N=48, Not yet recruiting, Sponsor: AstraZeneca
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jun 27, 2017
P2, N=120, Recruiting, Sponsor: Assiut University
Recruiting --> Completed | N=120 --> 212 | Trial primary completion date: Aug 2017 --> May 2017 Trial primary completion date: Feb 2017 --> Aug 2017
- | Sustol (granisetron ER) / Heron Therapeutics
Journal: APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. (Pubmed Central) - Jun 7, 2017
Trial primary completion date: Feb 2017 --> Aug 2017 APF530 plus fosaprepitant and dexamethasone effectively prevented CINV among patients receiving AC-based HEC, a large subgroup in whom CINV control has traditionally been challenging.
- | Sustol (granisetron ER) / Heron Therapeutics
Journal: APF530 (Granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. (Pubmed Central) - Mar 9, 2017
P3
APF530 versus the standard three-drug regimen provided superior control of delayed-phase CINV following HEC. ClinicalTrials.gov : NCT02106494.
- | Sancuso (granisetron) / Cumberland
Trial initiation date, Trial primary completion date: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (clinicaltrials.gov) - Mar 3, 2017
P1, N=16, Not yet recruiting, Sponsor: Kyowa Kirin Pharmaceutical Development Ltd
ClinicalTrials.gov : NCT02106494. Initiation date: Jul 2014 --> Jul 2018 | Trial primary completion date: Oct 2015 --> Dec 2018
- | Sancuso (granisetron) / Cumberland
Trial initiation date, Trial primary completion date: Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years (clinicaltrials.gov) - Mar 3, 2017
P1, N=16, Not yet recruiting, Sponsor: Kyowa Kirin Pharmaceutical Development Ltd
Initiation date: Jul 2014 --> Jul 2018 | Trial primary completion date: Oct 2015 --> Dec 2018 Initiation date: May 2014 --> May 2017 | Trial primary completion date: May 2015 --> Dec 2017
- granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jan 26, 2017
P2, N=120, Recruiting, Sponsor: Assiut University
Initiation date: May 2014 --> May 2017 | Trial primary completion date: May 2015 --> Dec 2017 Trial primary completion date: Sep 2016 --> Feb 2017
- | cabazitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - Jan 24, 2017
P4, N=21, Completed, Sponsor: Sanofi
Trial primary completion date: Sep 2016 --> Feb 2017 Active, not recruiting --> Completed
- Sancuso (granisetron) / Cumberland
Trial completion, Trial primary completion date: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (clinicaltrials.gov) - Jan 23, 2017
P1, N=19, Completed, Sponsor: Kyowa Kirin Pharmaceutical Development Ltd
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015
- granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
Trial primary completion date: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Jun 18, 2016
P2, N=120, Recruiting, Sponsor: Assiut University
Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Aug 2015 Trial primary completion date: May 2016 --> Aug 2016
- | cabazitaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - Mar 30, 2016
P4, N=21, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: May 2016 --> Aug 2016 Recruiting --> Active, not recruiting
- Sancuso (granisetron) / Cumberland
Enrollment closed, Trial primary completion date: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (clinicaltrials.gov) - Dec 17, 2015
P1, N=16, Active, not recruiting, Sponsor: Prostrakan Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016
- | granisetron oral / Generic mfg., granisetron intravenous / Generic mfg.
New P2 trial: Prevention of Spinal Induced Shivering During CS (clinicaltrials.gov) - Oct 28, 2015
P2, N=120, Recruiting, Sponsor: Assiut University
- | cabazitaxel / Generic mfg.
New P4 trial, Combination therapy, Metastases: PEGAZUS: Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer (clinicaltrials.gov) - May 12, 2015
P4, N=25, Recruiting, Sponsor: Sanofi
- Enrollment closed, Surgery, Metastases: PRECISO: Observational Study of Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=61, Active, not recruiting, Sponsor: Grupo Oncologico Cooperativo Chileno de Investigation
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2016 Recruiting --> Active, not recruiting
- granisetron intravenous / Generic mfg.
Enrollment change: Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients (clinicaltrials.gov) - Jan 28, 2015
P2, N=31, Completed, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Recruiting --> Active, not recruiting N=25 --> 31
- Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma (clinicaltrials.gov) - Aug 8, 2014
P2, N=22, Active, not recruiting, Sponsor: University of Miami
N=25 --> 31 Trial primary completion date: Apr 2014 --> Apr 2015
- Sancuso (granisetron) / Cumberland
Trial initiation date: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (clinicaltrials.gov) - Jan 22, 2014
P1, N=16, Not yet recruiting, Sponsor: Prostrakan Pharmaceuticals
Trial primary completion date: Apr 2014 --> Apr 2015 Initiation date: Jul 2013 --> Jul 2014
- Sancuso (granisetron) / Cumberland
Trial initiation date: Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years (clinicaltrials.gov) - Jan 22, 2014
P1, N=16, Not yet recruiting, Sponsor: Prostrakan Pharmaceuticals
Initiation date: Jul 2013 --> Jul 2014 Initiation date: Mar 2013 --> May 2014
- Sancuso (granisetron) / Cumberland
Enrollment open: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (clinicaltrials.gov) - Nov 28, 2012
P1, N=16, Recruiting, Sponsor: Prostrakan Pharmaceuticals
Initiation date: Mar 2013 --> May 2014 Not yet recruiting --> Recruiting
- Sustol (granisetron ER) / Heron Therapeutics
Trial completion: A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin (clinicaltrials.gov) - Oct 23, 2012
P1, N=56, Completed, Sponsor: A.P. Pharma, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Surgery, Metastases: PRECISO: Observational Study of Perioperative Chemotherapy in Gastric Cancer (clinicaltrials.gov) - Jul 2, 2012
P=N/A, N=75, Recruiting, Sponsor: Grupo Oncologico Cooperativo Chileno de Investigation
- | Sancuso (granisetron) / Cumberland
New P1 trial: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years (clinicaltrials.gov) - May 9, 2012
P1, N=16, Not yet recruiting, Sponsor: Prostrakan Pharmaceuticals
- | Sancuso (granisetron) / Cumberland
New P1 trial: Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years (clinicaltrials.gov) - May 9, 2012
P1, N=16, Not yet recruiting, Sponsor: Prostrakan Pharmaceuticals
- | Sancuso (granisetron) / Cumberland
New P1 trial: Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 Years (clinicaltrials.gov) - May 9, 2012
P1, N=16, Recruiting, Sponsor: Prostrakan Pharmaceuticals
- Sustol (granisetron ER) / Heron Therapeutics
New P1 trial: A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin (clinicaltrials.gov) - Aug 11, 2011
P1, N=56, Completed, Sponsor: A.P. Pharma, Inc.